Q1 Earnings Estimate for VYGR Issued By Leerink Partnrs

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Voyager Therapeutics in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo anticipates that the company will post earnings of ($0.17) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and Q4 2025 earnings at ($0.17) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the firm posted ($0.59) earnings per share.

A number of other analysts have also recently weighed in on the stock. Wedbush started coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Trading Up 1.6 %

VYGR stock opened at $5.62 on Friday. The stock’s 50 day simple moving average is $5.80 and its 200 day simple moving average is $6.63. Voyager Therapeutics has a 12-month low of $4.99 and a 12-month high of $10.66. The firm has a market cap of $307.00 million, a P/E ratio of 7.92 and a beta of 0.93.

Insider Buying and Selling

In other news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 10,778 shares of company stock valued at $58,548 over the last 90 days. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares in the last quarter. Barclays PLC grew its position in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after buying an additional 37,398 shares during the last quarter. Geode Capital Management LLC grew its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $6,192,000. Finally, Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $216,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.